Spots Global Cancer Trial Database for neurofibromatosis 1
Every month we try and update this database with for neurofibromatosis 1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Real-World Treatment Study of Koselugo (Selumetinib) | NCT06360406 | Neurofibromatos... Neurofibroma, P... | 3 Years - 18 Years | AstraZeneca | ||
| Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1 | NCT04941027 | Neurofibromatos... | 40 Years - | Stanford University | ||
| From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 | NCT03826940 | Autism Spectrum... Neurofibromatos... | Lovastatin 60 M... Placebos | 16 Years - 65 Years | University of Coimbra | |
| RASopathy Biorepository | NCT04395495 | RAS Mutation Neurofibromatos... Noonan Syndrome Noonan Syndrome... Noonan Neurofib... Cardiofaciocuta... Costello Syndro... Legius Syndrome Smith-Kingsmore... MTOR Gene Mutat... GATOR-1 Gene Mu... SYNGAP1-Related... DLG4 MAPK1 Gene Muta... | - | Children's Hospital Medical Center, Cincinnati | ||
| Treatment of NF1-related Plexiform Neurofibroma With Trametinib | NCT03741101 | Neurofibromatos... Child Neurofibroma, P... | Trametinib | 1 Year - 17 Years | Region Skane | |
| Study About Annoucement of the Diagnosis of Neurofibromatosis 1 in de Novo Forms | NCT03298438 | Neurofibromatos... Diagnoses Disea... Post Traumatic ... | 18 Years - | University Hospital, Brest | ||
| NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | NCT04435665 | Neurofibromatos... Cutaneous Neuro... | NFX-179 Gel Vehicle Gel | 18 Years - | NFlection Therapeutics, Inc. | |
| Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1 | NCT05912400 | Neurofibromatos... | Blood draw FACIT-F and Pai... | 18 Years - | University of Arkansas | |
| HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas | NCT05331105 | Neurofibromatos... Plexiform Neuro... | HL-085 | 18 Years - 80 Years | Shanghai Kechow Pharma, Inc. | |
| Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 | NCT03090971 | Neurofibromatos... Cutaneous Neuro... | Diclofenac Sodi... Saline Solution | 18 Years - | Fundação Educacional Serra dos Órgãos | |
| Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial | NCT04561765 | Neurofibromatos... Chronic Pain | iCanCope iCanCope+Contin... | 18 Years - 72 Years | Yale University | |
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | NCT05849662 | Leukemia, Juven... JMML JCML Neurofibromatos... CBL Syndrome | Trametinib Azacitidine Fludarabine Cytarabine | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Natural History Study of Cutaneous Neurofibromas in People With NF1 | NCT05581511 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Cutaneous Neuro... | Evaluation of t... | 1 Year - 100 Years | Johns Hopkins University | |
| Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 | NCT03090971 | Neurofibromatos... Cutaneous Neuro... | Diclofenac Sodi... Saline Solution | 18 Years - | Fundação Educacional Serra dos Órgãos | |
| Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) | NCT06222203 | Neurofibromatos... Nerve Sheath Ne... | 3 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | NCT05849662 | Leukemia, Juven... JMML JCML Neurofibromatos... CBL Syndrome | Trametinib Azacitidine Fludarabine Cytarabine | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Neurofibromatosis (NF) Registry Portal | NCT01885767 | Neurofibromatos... Neurofibromatos... Schwannomatosis | - | The Children's Tumor Foundation | ||
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas | NCT03231306 | Neurofibromatos... Plexiform Neuro... | Binimetinib | 1 Year - | University of Alabama at Birmingham | |
| Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN) | NCT04774289 | Neurofibromatos... Peripheral Nerv... | 1 Month - | National Institutes of Health Clinical Center (CC) | ||
| NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | NCT05005845 | Cutaneous Neuro... Neurofibromatos... | NFX-179 gel Vehicle gel | 18 Years - | NFlection Therapeutics, Inc. | |
| Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 | NCT04481035 | Neurofibromatos... | N-acetylcystein... Placebo | 8 Years - 16 Years | Children's Hospital Medical Center, Cincinnati | |
| Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas | NCT04750928 | Neurofibromatos... | Abemaciclib | 12 Years - | National Institutes of Health Clinical Center (CC) | |
| NF-1, Nutraceutical Intervention | NCT05363267 | Neurofibromatos... | curcumin, high ... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors | NCT03433183 | Malignant Perip... Neurofibromatos... | Selumetinib Sirolimus | 12 Years - | Sarcoma Alliance for Research through Collaboration | |
| Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) | NCT00352599 | Neurofibromatos... | Lovastatin Lovastatin placebo pill | 10 Years - 50 Years | University of California, Los Angeles | |
| Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1 | NCT05238909 | Neurofibromatos... NF1 Neurofibromatos... | - | Ann & Robert H Lurie Children's Hospital of Chicago | ||
| Internet Support Group for Parents of a Child With Neurofibromatosis Type 1 | NCT02153931 | Neurofibromatos... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) | NCT06222203 | Neurofibromatos... Nerve Sheath Ne... | 3 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN) | NCT04774289 | Neurofibromatos... Peripheral Nerv... | 1 Month - | National Institutes of Health Clinical Center (CC) | ||
| Genetic Evaluation of NF1 and Scoliosis Patients | NCT01776125 | Neurofibromatos... Scoliosis | Cheek swab | 6 Years - 65 Years | University of Minnesota | |
| Treatment of NF1-related Plexiform Neurofibroma With Trametinib | NCT03741101 | Neurofibromatos... Child Neurofibroma, P... | Trametinib | 1 Year - 17 Years | Region Skane | |
| Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1 | NCT04991428 | Neurofibromatos... | Transcranial di... | 11 Years - 17 Years | University of Manchester | |
| Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1 | NCT05196854 | Hypertension Neurofibromatos... Blood Pressure | Group 1. Standa... Group 2. Hypnos... | 5 Years - 18 Years | Murdoch Childrens Research Institute | |
| Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 | NCT04481048 | Neurofibromatos... | N-Acetyl cystei... Placebo | 8 Years - 16 Years | Children's Hospital Medical Center, Cincinnati | |
| Treatment of NF1-related Plexiform Neurofibroma With Trametinib | NCT03741101 | Neurofibromatos... Child Neurofibroma, P... | Trametinib | 1 Year - 17 Years | Region Skane | |
| Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1 | NCT04991428 | Neurofibromatos... | Transcranial di... | 11 Years - 17 Years | University of Manchester | |
| Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas | NCT04924608 | Neurofibromatos... Plexiform Neuro... | Selumetinib Placebo | 18 Years - | AstraZeneca | |
| Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing | NCT03406208 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Schwannomatosis | Stress and Symp... Stress and Symp... | 18 Years - | Massachusetts General Hospital | |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | NCT04954001 | Neurofibromatos... Plexiform Neuro... NF1 | FCN-159 | 2 Years - 70 Years | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 | NCT06188741 | Neurofibromatos... Plexiform Neuro... | Selumetinib | 1 Year - 8 Years | University of Alabama at Birmingham | |
| Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs) | NCT02544022 | Neurofibromatos... Plexiform Neuro... | 5 Years - | National Institutes of Health Clinical Center (CC) | ||
| Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1 | NCT05677594 | Neurofibromatos... Malignant Perip... Atypical Neurof... | Whole Body Magn... | 6 Years - | Johns Hopkins University | |
| A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) | NCT04590235 | Neurofibromatos... Neurofibroma Pl... | Selumetinib | 3 Years - 99 Years | AstraZeneca | |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | NCT04954001 | Neurofibromatos... Plexiform Neuro... NF1 | FCN-159 | 2 Years - 70 Years | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1 | NCT05377008 | Neurocognitive ... Mental Health I... Neurofibromatos... | OPTIMAL-SSI | 6 Years - 16 Years | Virginia Commonwealth University | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE) | NCT06379230 | Neurofibromatos... Plexiform Neuro... | This study is p... | - | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1 | NCT06262113 | Neurofibromatos... | Letters about N... Letters about N... | 18 Years - | Massachusetts General Hospital | |
| Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II | NCT02728388 | NEUROFIBROMATOS... | aminolevulinic ... | 14 Years - 30 Years | Medical College of Wisconsin | |
| Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T | NCT02332902 | Neurofibromatos... | Everolimus | 18 Years - | The University of Texas Health Science Center, Houston | |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | NCT04954001 | Neurofibromatos... Plexiform Neuro... NF1 | FCN-159 | 2 Years - 70 Years | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| Assessing the Efficacy of Repeat, Monthly Treatments of Cutaneous Neurofibromas (cNFs) | NCT06300502 | Neurofibromas, ... Neurofibromatos... | Kybella Asclera 755nm Alexandri... 1064nm Nd:YAG L... | 18 Years - 85 Years | Massachusetts General Hospital | |
| Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis | NCT01777451 | Whole Body Imag... Magnetic Resona... Neurofibromatos... Diffusion Magne... Peripheral Nerv... | Additional imag... | 6 Years - 50 Years | Universitaire Ziekenhuizen KU Leuven | |
| FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas | NCT05913037 | Neurofibromatos... Plexiform Neuro... NF1 | Test group (Gro... Control group (... | 18 Years - 70 Years | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE) | NCT06379230 | Neurofibromatos... Plexiform Neuro... | This study is p... | - | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Dosing and Tolerability of Deoxycholic Acid Versus Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas | NCT06120036 | Neurofibromatos... | Kybella Asclera | 18 Years - 85 Years | Massachusetts General Hospital | |
| AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors | NCT01362803 | Neurofibromatos... Neurofibromatos... NF1 Neurofibroma, P... | AZD6244 | 2 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial | NCT05361811 | Neurofibromatos... Noonan Syndrome Legius Syndrome Cardiofaciocuta... Costello Syndro... | Waitlist ACT Interventio... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs) | NCT02544022 | Neurofibromatos... Plexiform Neuro... | 5 Years - | National Institutes of Health Clinical Center (CC) | ||
| Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas | NCT06132165 | Neurofibromatos... | Deoxycholic Aci... Polidocanol 1064nm Nd:YAG l... 755nm Alexandri... | 18 Years - 80 Years | Massachusetts General Hospital | |
| Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs) | NCT02544022 | Neurofibromatos... Plexiform Neuro... | 5 Years - | National Institutes of Health Clinical Center (CC) | ||
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | NCT03962543 | Plexiform Neuro... Neurofibromatos... | Mirdametinib (P... | 2 Years - | SpringWorks Therapeutics, Inc. | |
| Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 | NCT03820778 | Neurofibromatos... Neurofibroma Atypical Neurof... Atypical Neurof... Plexiform Neuro... Von Recklinghau... | Whole Body MRI | 8 Years - 30 Years | Children's National Research Institute | |
| Genetic Evaluation of NF1 and Scoliosis Patients | NCT01776125 | Neurofibromatos... Scoliosis | Cheek swab | 6 Years - 65 Years | University of Minnesota | |
| Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 | NCT04481035 | Neurofibromatos... | N-acetylcystein... Placebo | 8 Years - 16 Years | Children's Hospital Medical Center, Cincinnati | |
| Medical Treatment of "High-Risk" Neurofibromas | NCT00846430 | Neurofibromatos... | Peg-Interferon ... Celecoxib (Cele... Temozolomide (t... Vincristine Sul... | 2 Years - 30 Years | Spectrum Health Hospitals | |
| RASopathy Biorepository | NCT04395495 | RAS Mutation Neurofibromatos... Noonan Syndrome Noonan Syndrome... Noonan Neurofib... Cardiofaciocuta... Costello Syndro... Legius Syndrome Smith-Kingsmore... MTOR Gene Mutat... GATOR-1 Gene Mu... SYNGAP1-Related... DLG4 MAPK1 Gene Muta... | - | Children's Hospital Medical Center, Cincinnati | ||
| Real-World Treatment Study of Koselugo (Selumetinib) | NCT06360406 | Neurofibromatos... Neurofibroma, P... | 3 Years - 18 Years | AstraZeneca | ||
| Medical Treatment of "High-Risk" Neurofibromas | NCT00846430 | Neurofibromatos... | Peg-Interferon ... Celecoxib (Cele... Temozolomide (t... Vincristine Sul... | 2 Years - 30 Years | Spectrum Health Hospitals | |
| Study About Annoucement of the Diagnosis of Neurofibromatosis 1 in de Novo Forms | NCT03298438 | Neurofibromatos... Diagnoses Disea... Post Traumatic ... | 18 Years - | University Hospital, Brest | ||
| Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial | NCT05361811 | Neurofibromatos... Noonan Syndrome Legius Syndrome Cardiofaciocuta... Costello Syndro... | Waitlist ACT Interventio... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas | NCT03231306 | Neurofibromatos... Plexiform Neuro... | Binimetinib | 1 Year - | University of Alabama at Birmingham | |
| NF-1, Nutraceutical Intervention | NCT05363267 | Neurofibromatos... | curcumin, high ... | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | NCT05735717 | Hematologic Mal... Acute Leukemia Remission Acute Myeloid L... Acute Lymphobla... AML TP53 Intrachromosoma... Cytogenetic Abn... CNS Leukemia Minimal Residua... Myelodysplasia Juvenile Myelom... Somatic Mutatio... PTPN11 Gene Mut... N-RAS Gene Ampl... Neurofibromatos... NF1 Mutation CBL Gene Mutati... Monosomy 7 Chromosome Abno... Fetal Hemoglobi... | Fludarabine Busulfan Melphalan Rituximab Levetiracetam | - 60 Years | Masonic Cancer Center, University of Minnesota | |
| From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 | NCT03826940 | Autism Spectrum... Neurofibromatos... | Lovastatin 60 M... Placebos | 16 Years - 65 Years | University of Coimbra | |
| Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1 | NCT02680431 | Neurofibromatos... | Blood sample | 18 Years - 85 Years | Turku University Hospital | |
| Pilot Randomized Control Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1 | NCT04860362 | Neurofibromatos... Social Skills | PEERS | 12 Years - 17 Years | University of Wisconsin, Milwaukee | |
| Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing | NCT03406208 | Neurofibromatos... Neurofibromatos... Neurofibromatos... Schwannomatosis | Stress and Symp... Stress and Symp... | 18 Years - | Massachusetts General Hospital | |
| Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis | NCT01777451 | Whole Body Imag... Magnetic Resona... Neurofibromatos... Diffusion Magne... Peripheral Nerv... | Additional imag... | 6 Years - 50 Years | Universitaire Ziekenhuizen KU Leuven | |
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | NCT03962543 | Plexiform Neuro... Neurofibromatos... | Mirdametinib (P... | 2 Years - | SpringWorks Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
